What to expect for SLS share price upon the 80th event announcement? A look back at the Celator (CPXX) Phase 3 precedent
I have close to 1000 shares meant for swing trading, apart from the 1.6K shares long (2.6K is very much above my risk threshold).
This got me wondering what I can expect the pop to look like on the announcement of the 80th event.
Claude gave me this answer, of a similar Therapeutic company,
Celator Pharmaceuticals (CPXX) — CPX-351 (Vyxeos) Phase 3 trial in high-risk AML
which ended up eventually getting bought out .
I am simply copy pasting what I found, I have not done any background deep dive research into this.
The Analogy: Small-cap, oncology, OS-driven, strong Phase 2 data beforehand, and a public "we hit the event threshold" announcement that's cleanly separable from the topline reveal weeks later.
Setup: previously reported Phase II data had already shown a survival benefit with CPX-351 versus standard chemotherapy in patients with secondary AML, so — like SLS — this was a small biotech riding real, positive earlier-phase efficacy signal into a single binary Phase 3 survival trial.
Design: it's structurally identical to REGAL — a randomized, controlled Phase 3 study comparing CPX-351 to standard 7+3 chemotherapy as first-line therapy in high-risk AML, with overall survival as the primary endpoint, requiring a pre-specified number of deaths before analysis could run.
The trigger announcement: On February 16, 2016, Celator announced its Phase 3 trial had reached its pre-specified number of events required for the overall survival analysis, and that it expected to announce the OS results later that quarter — this is the exact "80th event" moment you're asking about. No data was unblinded yet; it was purely "we've hit the number, now the clock starts."
Stock reaction to that trigger (not the data): It was large. Shares jumped more than 30% on the news that Celator had reached the number of events required for analysis, trading around $1.80 in the days after. That's a dramatically bigger move than Esperion's ~6% — likely because Celator was a tiny, single-asset, pre-commercial company where this trial was effectively the entire investment thesis (much closer to SLS's situation than Esperion, which had two approved drugs cushioning the stock).
My own search: The stock was trading at $1.42 on Feb 5, 2016 and then dipped to $1.2 on Feb 11 2016. From there on, it peaked back up to $1.41 at the close of Feb 16, 2016. Then, the price mooned and shot up to a peak of $2.52 and closed at $2.37 on Feb 22, 2016. So, we can see a gain of approx 67% when comparing the price at closing of days Feb 11 & Feb 22, 2016.
The link for the price chart: https://www.investing.com/equities/celator-pharm-chart
The quiet period: ran almost exactly the length SLS has guided to. The trigger was announced Feb 16; the positive topline survival results were announced the night of Monday, March 14, 2016 — call it about 4 weeks, right in your 1–4 week range.
What happened next: the actual data was strongly positive — CPX-351 reduced the risk of death by 31% versus 7+3, with a statistically significant 3.6-month median OS improvement — and the stock kept running from there; Celator shares were up roughly 1,610% for the year by late June 2016, as Jazz Pharmaceuticals moved to acquire the company shortly after.
If there are any factual inaccuracies, or false equivalences or claims made, please feel free to dispute or argue. I am not a well-versed investor and this is just AI work, just to get an idea of what to expect for the 80th event announcement and thought I'd share here.
TLDR: I have swing shares of 1K and wanted to know by how much I can expect the stock price to increase when 80th event is announced. On a similar clinical trial that happened in 2016, when they announced the event trigger, the stock price increased nearly 67%.